Loading
A phase 2/3 trial of Ipilimumab, Nivolumab in melanoma and uveal melanoma, run by Replimune, Inc., now recruiting.
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma is a phase 2/3 interventional study registered as NCT06581406 by Replimune, Inc., with 280 participants planned, started 2024-12-17 and due to reach its primary completion in 2030-01. Interventions recorded: RP2, Ipilimumab, Nivolumab. Conditions listed: Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Replimune, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Uveal melanoma, Ipilimumab, Melanoma, Immune checkpoint inhibitors.
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Shares Ipilimumab, Nivolumab, Immune checkpoint inhibitors.
Shares Ipilimumab, Nivolumab, Immune checkpoint inhibitors.
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/